| 5.67 -0.01 (-0.18%) | 01-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.73 | 1-year : | 7.87 |
| Resists | First : | 5.76 | Second : | 6.73 |
| Pivot price | 5.58  |
|||
| Supports | First : | 5.48 | Second : | 5.3 |
| MAs | MA(5) : | 5.63 |
MA(20) : | 5.57 |
| MA(100) : | 5.67 |
MA(250) : | 5.13 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 89.8 |
D(3) : | 82.2 |
| RSI | RSI(14): 56.6 |
|||
| 52-week | High : | 9.02 | Low : | 3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GBIO ] has closed below upper band by 28.0%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 47 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.69 - 5.73 | 5.73 - 5.76 |
| Low: | 5.52 - 5.57 | 5.57 - 5.6 |
| Close: | 5.6 - 5.68 | 5.68 - 5.74 |
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Fri, 23 Jan 2026
Halper Sadeh LLC Encourages DHIL, GBIO, CTGO Shareholders to Contact the Firm to Discuss Their Rights - Finviz
Thu, 22 Jan 2026
Halper Sadeh Investigates Shareholder Rights Violations at Diamond Hill, Generation Bio, and Contango - Intellectia AI
Tue, 16 Dec 2025
Generation Bio (GBIO) Rating Update: Wedbush Upgrades to Outperf - GuruFocus
Tue, 16 Dec 2025
XOMA Strikes Deal To Acquire Generation Bio, Expanding Royalty Portfolio - Nasdaq
Mon, 15 Dec 2025
Shareholder Alert: The Ademi Firm investigates whether Generation Bio Co. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Mon, 15 Dec 2025
XOMA Royalty Enters into Agreement to Acquire Generation Bio - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 4.19e+006 (%) |
| Held by Institutions | 14.2 (%) |
| Shares Short | 49 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.638e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 19.9 % |
| Return on Equity (ttm) | -27.4 % |
| Qtrly Rev. Growth | 1.527e+007 % |
| Gross Profit (p.s.) | -38.49 |
| Sales Per Share | -39.42 |
| EBITDA (p.s.) | -1.58049e+007 |
| Qtrly Earnings Growth | -9.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -114 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.15 |
| Price to Cash Flow | 1.54 |
| Dividend | 0 |
| Forward Dividend | 37730 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|